Dr. Agarwal's Health
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
By Vibhuti Sharma
MUMBAI, July 13 (Reuters) - India's Maxivision Super Specialty Eye Hospitals, backed by healthcare-focused buyout firm Quadria Capital, has appointed ICICI Securities and IIFL Capital as bankers for a planned 2027 initial public offering, two people familiar with the matter said.
Founded in 1996, Maxivision operates more than 90 eye-care centres across six states. It competes with chains including Dr. Agarwal's Health Care, Centre for Sight and ASG Eye Hospitals in a fast-growing market driven by an ageing population, rising diabetes rates and broader health insurance coverage.
India's eye-care market is projected to grow to $31.2 billion by 2033 from $12.8 billion in 2025, according to Grand View Research.
The Hyderabad-based company is in the early stages of preparing for the IPO, which will include a mix of newly-issued shares and stock sold by existing investors, the sources said.
The size of the IPO has not yet been finalised, they added, requesting anonymity because the talks are private.
Maxivision declined to comment, while ICICI Securities, IIFL Capital and Quadria Capital did not immediately respond to Reuters' queries.
Maxivision's listing plans come amid growing dealmaking and capital markets activity in India's healthcare sector.
Last month, Reuters reported that KKR was in advanced talks to acquire a majority stake in Sweden-based Medicover's MCOVb.ST Indian business for at least $1 billion. Earlier this year, Manipal Health Enterprises filed for an IPO that could raise up to $1.17 billion.
(Reporting by Vibhuti Sharma in Mumbai. Editing by Mark Potter)
(([email protected];))
By Vibhuti Sharma
MUMBAI, July 13 (Reuters) - India's Maxivision Super Specialty Eye Hospitals, backed by healthcare-focused buyout firm Quadria Capital, has appointed ICICI Securities and IIFL Capital as bankers for a planned 2027 initial public offering, two people familiar with the matter said.
Founded in 1996, Maxivision operates more than 90 eye-care centres across six states. It competes with chains including Dr. Agarwal's Health Care, Centre for Sight and ASG Eye Hospitals in a fast-growing market driven by an ageing population, rising diabetes rates and broader health insurance coverage.
India's eye-care market is projected to grow to $31.2 billion by 2033 from $12.8 billion in 2025, according to Grand View Research.
The Hyderabad-based company is in the early stages of preparing for the IPO, which will include a mix of newly-issued shares and stock sold by existing investors, the sources said.
The size of the IPO has not yet been finalised, they added, requesting anonymity because the talks are private.
Maxivision declined to comment, while ICICI Securities, IIFL Capital and Quadria Capital did not immediately respond to Reuters' queries.
Maxivision's listing plans come amid growing dealmaking and capital markets activity in India's healthcare sector.
Last month, Reuters reported that KKR was in advanced talks to acquire a majority stake in Sweden-based Medicover's MCOVb.ST Indian business for at least $1 billion. Earlier this year, Manipal Health Enterprises filed for an IPO that could raise up to $1.17 billion.
(Reporting by Vibhuti Sharma in Mumbai. Editing by Mark Potter)
(([email protected];))
May 15 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:
DR. AGARWAL'S HEALTH CARE LTD - GTES TAX NOTICE OF 150.8 MILLION RUPEES PLUS INTEREST AND PENALTY
Source text: ID:nNSE9fp8VP
Further company coverage: DRAA.NS
(([email protected];))
May 15 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:
DR. AGARWAL'S HEALTH CARE LTD - GTES TAX NOTICE OF 150.8 MILLION RUPEES PLUS INTEREST AND PENALTY
Source text: ID:nNSE9fp8VP
Further company coverage: DRAA.NS
(([email protected];))
Feb 3 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:
DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL NET PAT 337.4 MILLION RUPEES
DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.3 BILLION RUPEES
Source text: [ID:]
Further company coverage: DRAA.NS
(([email protected];;))
Feb 3 (Reuters) - Dr. Agarwal's Health Care Ltd DRAA.NS:
DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL NET PAT 337.4 MILLION RUPEES
DR. AGARWAL'S HEALTH CARE DEC-QUARTER CONSOL REVENUE FROM OPERATIONS 5.3 BILLION RUPEES
Source text: [ID:]
Further company coverage: DRAA.NS
(([email protected];;))
** Kotak starts coverage on India's Dr Agarwal's Health Care DRAA.NS with "add" and a fair value of 425 rupees
** Brokerage says high-priced surgical cases, which comprise 62%-65% of the total cases, will boost overall revenue for the eye care services provider over FY28
** Kotak's PT represents a 7.6% upside to DRAA's current price of 394.85 rupees; however, stock down 2% on the day
** Adds, DRAA's strong EBITDA growth trajectory broadly compensates for its currently lower, albeit, improving margins
** Avg rating of three analysts, excluding Kotak, at "buy"; median PT is 502 rupees - data compiled by LSEG
** Stock down 1.7% since trading debut in February
(Reporting by Kashish Tandon in Bengaluru)
** Kotak starts coverage on India's Dr Agarwal's Health Care DRAA.NS with "add" and a fair value of 425 rupees
** Brokerage says high-priced surgical cases, which comprise 62%-65% of the total cases, will boost overall revenue for the eye care services provider over FY28
** Kotak's PT represents a 7.6% upside to DRAA's current price of 394.85 rupees; however, stock down 2% on the day
** Adds, DRAA's strong EBITDA growth trajectory broadly compensates for its currently lower, albeit, improving margins
** Avg rating of three analysts, excluding Kotak, at "buy"; median PT is 502 rupees - data compiled by LSEG
** Stock down 1.7% since trading debut in February
(Reporting by Kashish Tandon in Bengaluru)
March 20 (Reuters) - ** Shares of Dr. Agarwal's Health Care DRAA.NS rise 7.5% to one-month high of 449 rupees
** Motilal Oswal Financial Services initiates coverage on stock with "buy" rating, PT of 510 rupees
** Co to outperform industry growth over the next five years amid latent demand for eye care, coupled with the firm's efforts to treat more patients at existing centers and add new centers, brokerage says
** Sees revenue and EBITDA growing at compounded annual rate of 23% and 21%, respectively, over FY25-FY27
** Higher penetration of insurance to drive an increase in patient volume, it says
** DRAA up nearly 12% after trading debut in early February
(Reporting by Vivek Kumar M)
(([email protected];))
March 20 (Reuters) - ** Shares of Dr. Agarwal's Health Care DRAA.NS rise 7.5% to one-month high of 449 rupees
** Motilal Oswal Financial Services initiates coverage on stock with "buy" rating, PT of 510 rupees
** Co to outperform industry growth over the next five years amid latent demand for eye care, coupled with the firm's efforts to treat more patients at existing centers and add new centers, brokerage says
** Sees revenue and EBITDA growing at compounded annual rate of 23% and 21%, respectively, over FY25-FY27
** Higher penetration of insurance to drive an increase in patient volume, it says
** DRAA up nearly 12% after trading debut in early February
(Reporting by Vivek Kumar M)
(([email protected];))
** Shares of recently listed Dr. Agarwal's Health Care DRAA.NS fall 2.8% to 411 rupees, its biggest one-day loss in a month
** Co says India's tax department has demanded payment of 427.4 million rupees ($4.92 million) from the health care co in taxes and penalties
** Co to take steps including filing an appeal against orders
** Stock up 2.2% since its listing on Feb. 4
($1 = 86.8325 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
** Shares of recently listed Dr. Agarwal's Health Care DRAA.NS fall 2.8% to 411 rupees, its biggest one-day loss in a month
** Co says India's tax department has demanded payment of 427.4 million rupees ($4.92 million) from the health care co in taxes and penalties
** Co to take steps including filing an appeal against orders
** Stock up 2.2% since its listing on Feb. 4
($1 = 86.8325 Indian rupees)
(Reporting by Aleef Jahan in Bengaluru)
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Dr. Agarwal's Health do?
Dr. Agarwal's Health Care provides a comprehensive range of eye care services, including cataract, refractive and other surgeries; consultations, diagnoses and non-surgical treatments; and sell opticals, contact lens and accessories, and eye care related pharmaceutical products. It endeavours to address all the needs of its patients in their eye treatment journey through a network.
Who are the competitors of Dr. Agarwal's Health?
Dr. Agarwal's Health major competitors are Apollo Hospital Ent., Max Healthcare Inst., Fortis Healthcare, Global Health, Narayana Hrudayalay., Krishna Inst.Medi, Aster DM Quality. Market Cap of Dr. Agarwal's Health is ₹15,645 Crs. While the median market cap of its peers are ₹70,845 Crs.
Is Dr. Agarwal's Health financially stable compared to its competitors?
Dr. Agarwal's Health seems to be less financially stable compared to its competitors. Altman Z score of Dr. Agarwal's Health is 6.38 and is ranked 6 out of its 8 competitors.
Does Dr. Agarwal's Health pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Dr. Agarwal's Health latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Dr. Agarwal's Health allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery
How strong is Dr. Agarwal's Health balance sheet?
Balance sheet of Dr. Agarwal's Health is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Dr. Agarwal's Health improving?
Yes, profit is increasing. The profit of Dr. Agarwal's Health is ₹168 Crs for TTM, ₹83.46 Crs for Mar 2025 and ₹83.06 Crs for Mar 2024.
Is the debt of Dr. Agarwal's Health increasing or decreasing?
Yes, The net debt of Dr. Agarwal's Health is increasing. Latest net debt of Dr. Agarwal's Health is ₹28.05 Crs as of Mar-26. This is greater than Mar-25 when it was -₹265.17 Crs.
Is Dr. Agarwal's Health stock expensive?
Dr. Agarwal's Health is not expensive. Latest PE of Dr. Agarwal's Health is 117, while 3 year average PE is 151. Also latest EV/EBITDA of Dr. Agarwal's Health is 27.52 while 3yr average is 29.02.
Has the share price of Dr. Agarwal's Health grown faster than its competition?
Dr. Agarwal's Health has given lower returns compared to its competitors. Dr. Agarwal's Health has grown at ~13.14% over the last 1yrs while peers have grown at a median rate of 14.8%
Is the promoter bullish about Dr. Agarwal's Health?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Dr. Agarwal's Health is 32.34% and last quarter promoter holding is 32.36%
Are mutual funds buying/selling Dr. Agarwal's Health?
The mutual fund holding of Dr. Agarwal's Health is increasing. The current mutual fund holding in Dr. Agarwal's Health is 6.02% while previous quarter holding is 5.87%.